
A phase 3 trial comparing capecitabine, capecitabine plus oxaliplatin (XELOX), and fluorouracil plus cisplatin (PF) in definitive concurrent chemoradiotherapy (DCRT) for inoperable locally advanced esophageal squamous cell carcinoma (ESCC) revealed similar 2-year overall survival (OS) rates among the groups (capecitabine: 75%, XELOX: 66.7%, PF: 70.9%). Median OS was comparable across arms. Grade ≥3 adverse events (AEs) were less frequent with capecitabine. Consolidation chemotherapy showed improved median OS compared to non-consolidation. Capecitabine or XELOX did not significantly outperform PF in inoperable locally advanced ESCC treatment.
Like
Save
Share